Rhonda D Szczesniak
Overview
Explore the profile of Rhonda D Szczesniak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szczesniak R, Andrinopoulou E, Li H, Jain R, Mayer-Hamblett N, Ostrenga J, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39929763
Background: Increased variability in forced expiratory volume in 1 s of % predicted (FEVpp) has been associated with accelerated lung function decline in individuals with cystic fibrosis (CF). Lung function...
2.
Colegate S, Palipana A, Gecili E, Szczesniak R, Brokamp C
J Clin Transl Sci
. 2024 Sep;
8(1):e94.
PMID: 39220818
Introduction: Patients with cystic fibrosis (CF) experience frequent episodes of acute decline in lung function called pulmonary exacerbations (PEx). An existing clinical and place-based precision medicine algorithm that accurately predicts...
3.
Peterson C, Rao M, Palipana A, Manning E, Vancil A, Ryan P, et al.
Sci Total Environ
. 2024 Aug;
950:175348.
PMID: 39117222
Environmental exposures and community characteristics have been linked to accelerated lung function decline in people with cystic fibrosis (CF), but geomarkers, the measurements of these exposures, have not been comprehensively...
4.
Todd J, Morgan W, Szczesniak R, Ostrenga J, OConnell O, Cromwell E, et al.
Ann Am Thorac Soc
. 2024 Jun;
21(10):1416-1420.
PMID: 38889346
Declines in percent predicted forced expiratory volume in 1 second (ppFEV) are an important marker of clinical progression of cystic fibrosis (CF). We examined ppFEV variability in relation to a...
5.
Zhou G, Wang Z, Palipana A, Andrinopoulou E, Afonso P, McPhail G, et al.
Respir Res
. 2024 Apr;
25(1):187.
PMID: 38678203
Background: Modulator therapies that seek to correct the underlying defect in cystic fibrosis (CF) have revolutionized the clinical landscape. Given the heterogeneous nature of lung disease progression in the post-modulator...
6.
Rosenfeld M, Cromwell E, Schechter M, Ren C, Flume P, Szczesniak R, et al.
J Cyst Fibros
. 2024 Mar;
23(3):443-449.
PMID: 38556415
Rationale: The American Thoracic Society recommended switching to race-neutral spirometry reference equations, as race is a social construct and to avoid normalizing disparities in lung function due to structural racism....
7.
Liou T, Argel N, Asfour F, Brown P, Chatfield B, Cox D, et al.
iScience
. 2024 Feb;
27(3):108835.
PMID: 38384849
Airway inflammation underlies cystic fibrosis (CF) pulmonary exacerbations. In a prospective multicenter study of randomly selected, clinically stable adolescents and adults, we assessed relationships between 24 inflammation-associated molecules and the...
8.
Wissel B, Greiner H, Glauser T, Pestian J, Ficker D, Cavitt J, et al.
Neurology
. 2024 Feb;
102(4):e208048.
PMID: 38315952
Background And Objectives: Epilepsy surgery is often delayed. We previously developed machine learning (ML) models to identify candidates for resective epilepsy surgery earlier in the disease course. In this study,...
9.
Palipana A, Vancil A, Gecili E, Rasnick E, Ehrlich D, Pestian T, et al.
Environ Adv
. 2023 Dec;
14.
PMID: 38094913
Background: Cystic fibrosis (CF) is a genetic disease but is greatly impacted by non-genetic (social/environmental and stochastic) influences. Some people with CF experience rapid decline, a precipitous drop in lung...
10.
Zhou G, Song S, Szczesniak R
Stat Med
. 2023 May;
42(17):2914-2927.
PMID: 37170074
Joint modeling has been a useful strategy for incorporating latent associations between different types of outcomes simultaneously, often focusing on a longitudinal continuous outcome characterized by an LME submodel and...